tiprankstipranks
Trending News
More News >
ChemoMetec A/S (GB:0DZ0)
LSE:0DZ0

ChemoMetec A/S (0DZ0) Price & Analysis

Compare
0 Followers

0DZ0 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

6.39%89.68%
Insiders
6.39%
Mutual Funds
― Other Institutional Investors
89.68% Public Companies and
Individual Investors

0DZ0 FAQ

What was ChemoMetec A/S’s price range in the past 12 months?
ChemoMetec A/S lowest share price was kr295.80 and its highest was kr613.50 in the past 12 months.
    What is ChemoMetec A/S’s market cap?
    ChemoMetec A/S’s market cap is €8.86B.
      When is ChemoMetec A/S’s upcoming earnings report date?
      ChemoMetec A/S’s upcoming earnings report date is Sep 11, 2025 which is in 106 days.
        How were ChemoMetec A/S’s earnings last quarter?
        ChemoMetec A/S released its earnings results on May 07, 2025. The company reported kr3.64 earnings per share for the quarter, beating the consensus estimate of kr3.47 by kr0.17.
          Is ChemoMetec A/S overvalued?
          According to Wall Street analysts ChemoMetec A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does ChemoMetec A/S pay dividends?
            ChemoMetec A/S pays a Annually dividend of kr4 which represents an annual dividend yield of 0.79%. See more information on ChemoMetec A/S dividends here
              What is ChemoMetec A/S’s EPS estimate?
              ChemoMetec A/S’s EPS estimate is -0.88.
                How many shares outstanding does ChemoMetec A/S have?
                ChemoMetec A/S has 17,402,480 shares outstanding.
                  What happened to ChemoMetec A/S’s price movement after its last earnings report?
                  ChemoMetec A/S reported an EPS of kr3.64 in its last earnings report, beating expectations of kr3.47. Following the earnings report the stock price went down -4.166%.
                    Which hedge fund is a major shareholder of ChemoMetec A/S?
                    Currently, no hedge funds are holding shares in GB:0DZ0

                    Company Description

                    ChemoMetec A/S

                    ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Allerød, Denmark.
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    ChemoMetec A/S
                    ChemoMetec A/S
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis